Neurocrine Biosciences chief medical officer sells $222,636 in stock

Eiry Roberts, the Chief Medical (TASE:PMCN) Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold shares of the company’s common stock. According to a recent SEC filing, Roberts sold 1,457 shares on January 31 at an average price of $152.8045 per share, totaling approximately $222,636. The transaction occurred near the stock’s 52-week high of $157.98, with InvestingPro data indicating the company currently trades at a premium to its Fair Value. This sale was part of a pre-arranged Rule 10b5-1 trading plan, which was adopted on September 1, 2022, and restricts modifications to the plan after its adoption.

Additionally, Roberts acquired 2,769 shares through the exercise of restricted stock units (RSUs), which were granted on January 31, 2022. These RSUs vested on January 31, 2025, as part of a scheduled vesting plan. Following these transactions, Roberts holds a total of 32,373 shares, with a significant portion held in a joint trust agreement where Roberts retains voting and investment power.

In other recent news, Neurocrine Biosciences has been the subject of several developments. Stifel analysts have maintained their positive outlook on Neurocrine Biosciences, following the company’s announcement of its altered partnership with Takeda on the AMPA program. Additionally, Neurocrine has sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism, focusing on classic congenital adrenal hyperplasia (CAH), a rare genetic condition.

Furthermore, Oppenheimer has reiterated its Outperform rating on Neurocrine Biosciences, highlighting the recent FDA approval of Crenessity for the treatment of CAH as a pivotal event for the company. Neurocrine Biosciences has also shared insights on the challenges of treating CAH with traditional glucocorticoids and the promise of new non-GC therapies.

Lastly, Piper Sandler has expressed continued confidence in Neurocrine Biosciences, reiterating an Overweight stock rating. These are recent developments that highlight the company’s ongoing progress in the biopharmaceutical market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.